S8
Track-Topic
ESTRO 2026
patients (100 %). Among those who underwent WBI, the cosmetic result was rated as ‘excellent’ by 63 out of 74 (85.2 %) surveyed patients (p = 0.003). Conclusion: In patients with early (T1-2N0M0) breast cancer APBI by high dose rate brachytherapy and WBI characterized by high efficacy with 97.7% and 98.3% local control with higher satisfaction of patients with cosmetic results after APBI. Keywords: APBI, early breast cancer, brachytherapy A novel form of breast IORT with CT-guided HDR brachytherapy: Final results of a prospective phase II clinical trial Lena M Turkheimer 1 , Gina R Petroni 2 , Melissa Lazar 3 , David R Brenin 1 , Anneke T Schroen 1 , Einsley M Janowski 4 , Bruce P Libby 5 , Timothy N Showalter 4 , Shayna L Showalter 1 1 Surgery, University of Virginia, Charlottesville, USA. 2 Public Health Sciences, University of Virginia, Charlottesville, USA. 3 Surgery, Thomas Jefferson Univeristy, Philadelphia, USA. 4 Radiation Oncology, University of Virginia, Charlottesville, USA. 5 Radiation Oncology, Moffitt Cancer Center, Tampa, USA Purpose/Objective: Conventional breast intraoperative radiation therapy (CB-IORT) delivers a single fraction of radiation during breast-conserving surgery (BCS), but lacks image Proffered Paper 1912 guidance and provides limited dosimetric optimization. Precision Breast IORT (PB-IORT) integrates intraoperative CT-based planning with high- dose-rate (HDR) brachytherapy, enabling individualized, image-guided radiation therapy. Following a Phase I feasibility study, this multicenter Phase II trial evaluated efficacy, toxicity, and cosmetic
effective alternative adjuvant radiation treatment for women with early breast cancer. Keywords: partial breast irradiation, multiplanar
Digital Poster 1702 Accelerated Partial Breast Irradiation: is it better than whole breast radiotherapy Sergey Nikolaevitch Novikov 1 , Bryantceva Zhanna 1 , Akulova Irina 1 , Melnik Julia 1 , Krivorotko Petr 2 , Ponomareva Olga 1 1 Radiotherapy, N.N. Petrov Cancer Institute, St Petersburg, Russian Federation. 2 Breast surgery, N.N. Petrov Cancer Institute, St Petersburg, Russian Federation Purpose/Objective: In single center prospective study to compare efficacy (five-year recurrence-free survival (RFS) and local control rate) and cosmetic results (according to self- assessment) of accelerated partial breast (APBI) or standard whole breast irradiation (WBI) in patients with early breast cancer (BC). Material/Methods: From 2016 to 2020, 208 women with pT1-2N0M0 BC underwent breast-conserving surgery and postoperative radiotherapy (RT). Of these patients, 87 underwent APBI, while another 121 were treated by WBI followed by an additional boost to the tumor bed in patients with triple negative or ERCBB2+ BC and in women younger than 45 y.o. APBI was performed by high dose-rate brachytherapy (64 patients) with 192Ir as 8 fractions of 4 Гр (2 fractions per day with at least 6hr interval) or by external beam radiotherapy (IMRT) as 5 fractions of 6 Gy once per day. WBI was delivered by tangential 6 MeV fields as 15 − 16 fractions of 2,66 Gy.A follow-up telephone survey assessing satisfaction with post-RT cosmetic outcomes was conducted with the 208 patients; 149 patients completed the BREAST- Q v2.0 questionnaire. Results: The median follow-up for the group that received APBI was 81 months [62; 88]. For the group of 121 patients who underwent WBI followed by additional irradiation of the tumor bed, the median follow-up was 64 months [54; 82]. Five-year local control rates in the ipsilateral breast were 97.7 % in the APBI group and 98.3 % in the WBI group (p = 0.95). Two local recurrences were detected in APBI group: one – on the border of irradiated volume, another – de novo BC of different subtype in another quadrant. Two local recurrences were revealed in WBI group: both close to the tumor bed. The five-year relapse free rates in the two groups were as follows: 93.8% after APBI and 95.9% after WBI (p = 0.52). The cosmetic results after APBI was rated as ‘excellent’ by all 75 evaluated
outcomes of PB-IORT. Material/Methods:
This multicenter Phase II trial enrolled women aged ≥ 45 years with clinical N0 invasive carcinoma (IDC) or DCIS ≤ 3 cm who underwent BCS from 2015 to 2022. After BCS, a multi-lumen catheter was placed, followed by intraoperative CT-guided HDR planning to deliver 12.5 Gy to the lumpectomy bed. The primary endpoint was 5-year index-quadrant tumor recurrence (IQTR). Secondary endpoints included locoregional and distant recurrence, overall survival, adverse events (AEs), cosmetic outcomes, and an exploratory comparison of pre- versus post-pathology treatment timing. Results: The final analysis cohort included 357 participants, with a median age of 63 and a median tumor size
Made with FlippingBook - Share PDF online